Kyle M Green1, Brian C Toy1, Bright S Ashimatey1, Debarshi Mustafi1, Richard L Jennelle2, Melvin A Astrahan2, Zhongdi Chu3, Ruikang K Wang3,4, Jonathan Kim1,5, Jesse L Berry1,5, Amir H Kashani1,6. 1. USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA. 2. Department of Radiation Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA. 3. Department of Bioengineering, University of Washington, Seattle, Washington. 4. Department of Ophthalmology, University of Washington, Seattle, Washington. 5. The Vision Center, Children's Hospital Los Angeles, Keck School of Medicine, Los Angeles, CA. 6. USC Ginsberg Institute for Biomedical Therapeutics, University of Southern California, Los Angeles, CA.
Abstract
PURPOSE: To assess longitudinal microvascular changes in eyes treated with I-125 episcleral plaque brachytherapy (EPB). METHODS: High resolution OCT angiograms of the central 3×3mm macula were obtained from I-125 episcleral plaque brachytherapy treated and untreated fellow eyes of 61 patients. Capillary density (vessel skeleton density, VSD) and caliber (vessel diameter index, VDI) were quantified using previously validated semi-automated algorithms. Nonperfusion was also quantified as flow impairment regions (FIR). Exams from treated and fellow eyes obtained pre-treatment and at 6-month, 1-year, and 2-year intervals were compared using generalized estimating equation linear models. Dosimetry maps were used to evaluate spatial correlation between radiation dose and microvascular metrics. RESULTS: At 6 months, treated eyes had significantly lower VSD (0.145 ± 0.003 vs 0.155 ± 0.002; p = 0.009) and higher FIR (2.01 ± 0.199 vs 1.46 ± 0.104; p = 0.010) compared to fellow eyes. There was a significant decrease in VSD and a corresponding increase in FIR even for treated eyes without clinically identifiable retinopathy at 6 months. VDI was significantly higher in treated eyes than in fellow eyes at 2 years (2.92 ± 0.025 vs 2.84 ± 0.018; p < 0.001). When our cohort was categorized into low dose radiation (<15Gy) and high dose radiation (>45Gy) to the fovea, there were significant differences in VSD and FIR between groups. CONCLUSIONS: OCTA can be used to quantify and monitor EPB induced retinopathy, and can detect vascular abnormalities even in the absence of clinically observable retinopathy. OCTA may therefore be useful in investigating treatment interventions that aim to delay EPB-induced radiation retinopathy.
PURPOSE: To assess longitudinal microvascular changes in eyes treated with I-125 episcleral plaque brachytherapy (EPB). METHODS: High resolution OCT angiograms of the central 3×3mm macula were obtained from I-125 episcleral plaque brachytherapy treated and untreated fellow eyes of 61 patients. Capillary density (vessel skeleton density, VSD) and caliber (vessel diameter index, VDI) were quantified using previously validated semi-automated algorithms. Nonperfusion was also quantified as flow impairment regions (FIR). Exams from treated and fellow eyes obtained pre-treatment and at 6-month, 1-year, and 2-year intervals were compared using generalized estimating equation linear models. Dosimetry maps were used to evaluate spatial correlation between radiation dose and microvascular metrics. RESULTS: At 6 months, treated eyes had significantly lower VSD (0.145 ± 0.003 vs 0.155 ± 0.002; p = 0.009) and higher FIR (2.01 ± 0.199 vs 1.46 ± 0.104; p = 0.010) compared to fellow eyes. There was a significant decrease in VSD and a corresponding increase in FIR even for treated eyes without clinically identifiable retinopathy at 6 months. VDI was significantly higher in treated eyes than in fellow eyes at 2 years (2.92 ± 0.025 vs 2.84 ± 0.018; p < 0.001). When our cohort was categorized into low dose radiation (<15Gy) and high dose radiation (>45Gy) to the fovea, there were significant differences in VSD and FIR between groups. CONCLUSIONS: OCTA can be used to quantify and monitor EPB induced retinopathy, and can detect vascular abnormalities even in the absence of clinically observable retinopathy. OCTA may therefore be useful in investigating treatment interventions that aim to delay EPB-induced radiation retinopathy.
Authors: Jesse L Berry; Savita V Dandapani; Marta Stevanovic; Thomas C Lee; Melvin Astrahan; A Linn Murphree; Jonathan W Kim Journal: JAMA Ophthalmol Date: 2013-11 Impact factor: 7.389
Authors: Alice Y Kim; Damien C Rodger; Anoush Shahidzadeh; Zhongdi Chu; Nicole Koulisis; Bruce Burkemper; Xuejuan Jiang; Kathryn L Pepple; Ruikang K Wang; Carmen A Puliafito; Narsing A Rao; Amir H Kashani Journal: Am J Ophthalmol Date: 2016-09-02 Impact factor: 5.258
Authors: Bao Han A Le; Jonathan W Kim; Hao Deng; Nadim Rayess; Richard L Jennelle; Sue Y Zhou; Melvin A Astrahan; Jesse L Berry Journal: Brachytherapy Date: 2018-08-03 Impact factor: 2.362
Authors: Tara A McCannel; EunAh Kim; Mitchell Kamrava; James Lamb; Joseph Caprioli; Dong Yang; Colin A McCannel Journal: Retina Date: 2018-12 Impact factor: 4.256
Authors: Sanket U Shah; Carol L Shields; Carlos G Bianciotto; Juan Iturralde; Saad A Al-Dahmash; Emil Anthony T Say; Josep Badal; Arman Mashayekhi; Jerry A Shields Journal: Ophthalmology Date: 2013-10-15 Impact factor: 12.079
Authors: Sam Kushner-Lenhoff; Kaitlin Kogachi; Melissa Mert; Zhongdi Chu; Anoush Shahidzadeh; Neal V Palejwala; Jeremy Wolfe; Sujit Itty; Kimberly A Drenser; Antonio Capone; Pravin U Dugel; Andrew A Moshfeghi; Hossein Ameri; Lauren P Daskivich; Ruikang K Wang; Amir H Kashani Journal: PLoS One Date: 2022-01-26 Impact factor: 3.240
Authors: Elaine M Binkley; Michelle R Tamplin; Anthony H Vitale; H Culver Boldt; Randy H Kardon; Isabella M Grumbach Journal: Am J Ophthalmol Case Rep Date: 2022-03-25